Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury
Key facts
- Who runs it
- University of Maryland, Baltimore
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 15 people, planned
- Started
- 26 Oct 2023
- Expected to end
- 26 Nov 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- Hyperpolarized 13C-Pyruvate
- Record updated
- 11 May 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- History of acute head injury with or suspected non-penetrating acute TBI
- Suitable to undergo contrast-enhanced MRI
- Negative serum pregnancy test
Who cannot take part
- Inability to receive IV MRI contrast agents secondary to severe reaction or renal insufficiency
- Inability to undergo MRI scan
- Positive pregnancy test
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial is currently available in United States.
- University of Maryland, BaltimoreBaltimore, United StatesContact: Rosy Linda Njonkou TchoquessiTaking people
About the trial
What the trial wants to find out
The purpose of this study is to examine the safety and feasibility of using hyperpolarized metabolic MRI to study early brain metabolism changes in subjects presenting with head injury and suspected non-penetrating traumatic brain injury (TBI). This study will also compare HP pyruvate MRI-derived metrics in TBI patients with healthy subjects as well as Subarachnoid hemorrhage (SAH) patients to better understand if metabolic Magnetic resonance imaging scan (MRI) can improve our ability to diagnose a TBI.
Read full original descriptionShow less
The FDA is allowing the use of hyperpolarized [1-13C] pyruvate (HP 13C-pyruvate) in this study.
Up to 15 patients (5 with TBI, 5 with SAH, and 5 healthy volunteers) may take part in this study at the University of Maryland, Baltimore (UMB).
The 3 groups in the trial
- Metabolic MRI in traumatic brain injury patientsTreatment being tested
Perform metabolic magnetic resonance imaging on patients who have traumatic brain injury to understand early brain metabolism changes in this population
Treatment: Hyperpolarized 13C-Pyruvate
- Metabolic MRI in subarachnoid hemorrhage patientsTreatment being tested
Perform metabolic magnetic resonance imaging on patients who have subarachnoid hemorrhage to understand early brain metabolism changes in this population
Treatment: Hyperpolarized 13C-Pyruvate
- Metabolic MRI in healthy volunteersTreatment being tested
Perform metabolic magnetic resonance imaging on healthy volunteers to understand early brain metabolism changes in this population
Treatment: Hyperpolarized 13C-Pyruvate
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Utility of Hyperpolarized 13C-Pyruvate Metabolic Magnetic Resonance Imaging in the Diagnosis of Early Cerebral Metabolic Crisis After Traumatic Brain Injury
- Criteria questions
- Built from NCT06103201, who can take part
- Record updated
- 11 May 2025